Robert E. Waltermire Madrigal Pharmaceuticals, Inc. (MDGL) insider trading activity

Robert E. Waltermire is Senior VP, Chief Pharma Dev. of MADRIGAL PHARMACEUTICALS, INC.. Currently has a direct ownership of 5,500 shares of MDGL, which is worth approximately $1.75 Million. The most recent transaction as insider was on Jun 14, 2024, when has been sold 1,900 shares (Common Stock) at a price of $280.0 per share, resulting in proceeds of $532,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.5K

0% 3M change

2.95% 12M change

Total Value Held $1.75 Million

Robert E. Waltermire Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 14 2024	SELL Open market or private sale	$532,000 $280.0 p/Share	1,900 Reduced 25.68%	5,500 Common Stock
Jun 14 2024	BUY Exercise of conversion of derivative security	$165,471 $87.09 p/Share	1,900 Added 20.43%	7,400 Common Stock
Jun 12 2024	SELL Open market or private sale	$570,000 $285.0 p/Share	2,000 Reduced 26.67%	5,500 Common Stock
Jun 12 2024	BUY Exercise of conversion of derivative security	$175,840 $87.92 p/Share	2,000 Added 21.05%	7,500 Common Stock
May 21 2024	SELL Open market or private sale	$239,668 $231.34 p/Share	1,036 Reduced 15.85%	5,500 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	1,419 Added 17.84%	6,536 Common Stock
Jan 16 2024	SELL Payment of exercise price or tax liability	$134,156 $243.92 p/Share	550 Reduced 9.71%	5,117 Common Stock
Dec 15 2023	SELL Open market or private sale	$477,000 $238.5 p/Share	2,000 Reduced 26.09%	5,667 Common Stock
Dec 15 2023	BUY Exercise of conversion of derivative security	$175,840 $87.92 p/Share	2,000 Added 20.69%	7,667 Common Stock
Dec 14 2023	SELL Open market or private sale	$465,000 $232.5 p/Share	2,000 Reduced 26.09%	5,667 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	$175,840 $87.92 p/Share	2,000 Added 20.69%	7,667 Common Stock
Dec 13 2023	SELL Open market or private sale	$563,750 $225.5 p/Share	2,500 Reduced 30.61%	5,667 Common Stock
Dec 13 2023	BUY Exercise of conversion of derivative security	$219,800 $87.92 p/Share	2,500 Added 23.44%	8,167 Common Stock
Dec 12 2023	SELL Open market or private sale	$282,750 $217.5 p/Share	1,300 Reduced 18.66%	5,667 Common Stock
Dec 12 2023	BUY Exercise of conversion of derivative security	$114,296 $87.92 p/Share	1,300 Added 15.73%	6,967 Common Stock
Mar 01 2023	SELL Open market or private sale	$1,374,650 $274.93 p/Share	5,000 Reduced 46.87%	5,667 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	$439,600 $87.92 p/Share	5,000 Added 31.91%	10,667 Common Stock
Feb 28 2023	SELL Open market or private sale	$1,358,300 $271.66 p/Share	5,000 Reduced 46.87%	5,667 Common Stock
Feb 28 2023	BUY Exercise of conversion of derivative security	$439,600 $87.92 p/Share	5,000 Added 31.91%	10,667 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	5,667 Added 50.0%	5,667 Common Stock

REW

Robert E. Waltermire

Senior VP, Chief Pharma Dev.

West Conshohocken, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MDGL shares.

Notify only if

Value

Insider Trading

Get notified when an Madrigal Pharmaceuticals, Inc. insider buys or sells MDGL shares.

Notify only if

Operation

Value

Type

News

Receive news related to MADRIGAL PHARMACEUTICALS, INC.

Track Activities on MDGL

Account